Nola Hylton, PhD
Professor
Radiology
School of Medicine
Nola Hylton, PhD, is a Professor in Residence in the Department of Radiology and Biomedical Imaging, and Director of the Breast Imaging Research Group at the University of California, San Francisco.
Show full bio (300 words) Hide full bio
Dr. Hylton received her BS in Chemical Engineering from the Massachusetts Institute of Technology in Cambridge, Massachusetts in 1979, and she obtained her PhD in Applied Physics from Stanford University, California in 1985.
Dr. Hylton has been integrally involved in the development of magnetic resonance imaging for the detection, diagnosis, and staging of breast cancer. Dr. Hylton is an internationally known leader in the field of breast MRI for more than 20 years. Her search has addressed the clinical optimization and evaluation of breast MRI technology. Her current research program focuses on the development and clinical evaluation of MRI techniques for characterizing breast cancers and assessing their response to treatment. Her laboratory collaborates closely with a multi-disciplinary team of radiologists, surgeons, oncologists, and science researchers nation wide. This is to optimize MRI techniques for the clinical management of breast cancer patients.
Dr. Hylton is among the first group of scholars named the Susan G. Komen for the Cure’s Scientific Advisory Council. She served as co-leader for the DHHS office of Women’s Health International Working Group where she identified and addressed barriers to clinical dissemination of breast MRI. She also served as the institutional Principal Investigator of the NCI International Breast MRI Consortium, which is the first large multi-center clinical trial evaluating breast MRI for breast cancer diagnosing and staging.
Dr. Hylton has over 80 published research articles, and she has written 13 book chapters and over 130 abstracts.
Expertise: Breast Imaging
Specialty: Breast cancer imaging, breast MRI
Professional Interests: Breast cancer, magnetic resonance imaging, medical imaging, breast cancer detection and diagnosis, treatment assessment, optical imaging, molecular imaging, functional imaging, small animal imaging
Education and Training:
- Bachelor of Science: Massachusetts Institute of Technology (MIT), Cambridge - Chemical Engineering
- Doctor of Philosophy: Stanford University, California - Applied Physics
Awards
Show all (8) Hide
- Distinguished Investigator, Academy of Radiology Research, 2013
- Cure Scholar Award, Komen, 2010
- Scientific Advisory Council, Susan G. Komen for the Cure's, 2010
- Research Scholar, American Cancer Society, 2003
- Outstanding Contribution Award, American College of Radiology Imaging Network, 2003
- Editor's Recognition Award with Distinction, Radiology, 1987-1988
- Graduate Professional Opportunities Program Fellowship, Stanford University, 1979
- Undergraduate Fellowship, Bell Telephone Laboratories, 1975
Interests
Show all (9) Hide
- magnetic resonance imaging
- molecular imaging
- Breast cancer
- breast cancer detection breast cancer diagnosis
- small animal imaging
- optical imaging
- treatment assessment
- functional imaging
- medical imaging
Websites
Show all (3) Hide
- Breast Imaging Research Group (radiology.ucsf.edu)
- Women's Imaging Clinical Section Research (radiology.ucsf.edu)
- Profile at UCSF Cancer Center (cancer.ucsf.edu)
Grants and Projects
Show all (6) Hide
- Real-time In Vivo MRI Biomarkers for Breast Cancer Pre-Operative Treatment Trials, NIH, 2008-2021
- Quantitative Imaging for Assessing Breast Cancer Response to Treatment, NIH, 2011-2016
- MRI For Staging DCIS and Assessing Response to Treatment, NIH, 2006-2013
- NMR Imaging and Spectroscopy, NIH, 1993-2013
- Anatomic and Biologic Staging of Breast Disease with MRI, NIH, 1997-2012
- Mechanism-Based Evaluations of ErbB-Targeted Agents, NIH, 2001-2008
Publications (190)
Top publication keywords:
Carcinoma, Intraductal, NoninfiltratingContrast MediaImage Interpretation, Computer-AssistedBreastReceptors, EstrogenDiffusion Magnetic Resonance ImagingMagnetic Resonance ImagingBreast NeoplasmsChemotherapy, AdjuvantArtifactsGadolinium DTPANeoadjuvant TherapyReceptor, ErbB-2Image EnhancementAntineoplastic Combined Chemotherapy Protocols
-
Cell-free DNA concentration as a biomarker of response and recurrence in HER2-negative breast cancer receiving neoadjuvant chemotherapy.
Clinical cancer research : an official journal of the American Association for Cancer Research 2024 Magbanua MJM, Ahmed Z, Sayaman RW, Brown Swigart L, Hirst GL, Yau C, Wolf DM, Li W, Delson AL, Perlmutter J, Pohlmann P, Symmans WF, Yee D, Hylton NM, Esserman LJ, DeMichele AM, Rugo HS, van 't Veer … -
18F-FDG Dedicated Breast PET Complementary to Breast MRI for Evaluating Early Response to Neoadjuvant Chemotherapy.
Radiology. Imaging cancer 2024 Diwanji D, Onishi N, Hathi DK, Lawhn-Heath C, Kornak J, Li W, Guo R, Molina-Vega J, Seo Y, Flavell RR, Heditsian D, Brain S, Esserman LJ, Joe BN, Hylton NM, Jones EF, Ray KM -
Neoadjuvant Trebananib plus Paclitaxel-based Chemotherapy for Stage II/III Breast Cancer in the Adaptively Randomized I-SPY2 Trial-Efficacy and Biomarker Discovery.
Clinical cancer research : an official journal of the American Association for Cancer Research 2024 Albain KS, Yau C, Petricoin EF, Wolf DM, Lang JE, Chien AJ, Haddad T, Forero-Torres A, Wallace AM, Kaplan H, Pusztai L, Euhus D, Nanda R, Elias AD, Clark AS, Godellas C, Boughey JC, Isaacs C, Tripathy… -
Breast Multiparametric MRI for Prediction of Neoadjuvant Chemotherapy Response in Breast Cancer: The BMMR2 Challenge.
Radiology. Imaging cancer 2024 Li W, Partridge SC, Newitt DC, Steingrimsson J, Marques HS, Bolan PJ, Hirano M, Bearce BA, Kalpathy-Cramer J, Boss MA, Teng X, Zhang J, Cai J, Kontos D, Cohen EA, Mankowski WC, Liu M, Ha R, Pellicer-… -
Protein signaling and drug target activation signatures to guide therapy prioritization: Therapeutic resistance and sensitivity in the I-SPY 2 Trial.
Cell reports. Medicine 2023 Gallagher RI, Wulfkuhle J, Wolf DM, Brown-Swigart L, Yau C, O'Grady N, Basu A, Lu R, Campbell MJ, Magbanua MJ, Coppé JP, I-SPY 2 Investigators, Asare SM, Sit L, Matthews JB, Perlmutter J, Hylton N, …
Show all (185 more) Hide
-
Effect of Longitudinal Variation in Tumor Volume Estimation for MRI-guided Personalization of Breast Cancer Neoadjuvant Treatment.
Radiology. Imaging cancer 2023 Onishi N, Bareng TJ, Gibbs J, Li W, Price ER, Joe BN, Kornak J, Esserman LJ, Newitt DC, Hylton NM, I-SPY 2 Imaging Working Group, I-SPY 2 Investigator Network -
Computational drug repositioning for the identification of new agents to sensitize drug-resistant breast tumors across treatments and receptor subtypes.
Frontiers in oncology 2023 Yu K, Basu A, Yau C, Wolf DM, Goodarzi H, Bandyopadhyay S, Korkola JE, Hirst GL, Asare S, DeMichele A, Hylton N, Yee D, Esserman L, van 't Veer L, Sirota M -
Comparison of Mammography AI Algorithms with a Clinical Risk Model for 5-year Breast Cancer Risk Prediction: An Observational Study.
Radiology 2023 Arasu VA, Habel LA, Achacoso NS, Buist DSM, Cord JB, Esserman LJ, Hylton NM, Glymour MM, Kornak J, Kushi LH, Lewis DA, Liu VX, Lydon CM, Miglioretti DL, Navarro DA, Pu A, Shen L, Sieh W, Yoon HC, Lee … -
Clinical significance and biology of circulating tumor DNA in high-risk early-stage HER2-negative breast cancer receiving neoadjuvant chemotherapy.
Cancer cell 2023 Magbanua MJM, Brown Swigart L, Ahmed Z, Sayaman RW, Renner D, Kalashnikova E, Hirst GL, Yau C, Wolf DM, Li W, Delson AL, Asare S, Liu MC, Albain K, Chien AJ, Forero-Torres A, Isaacs C, Nanda R, … -
Radiomic tumor phenotypes augment molecular profiling in predicting recurrence free survival after breast neoadjuvant chemotherapy.
Communications medicine 2023 Chitalia R, Miliotis M, Jahani N, Tastsoglou S, McDonald ES, Belenky V, Cohen EA, Newitt D, Van't Veer LJ, Esserman L, Hylton N, DeMichele A, Hatzigeorgiou A, Kontos D -
Deep Learning to Simulate Contrast-enhanced Breast MRI of Invasive Breast Cancer.
Radiology 2023 Chung M, Calabrese E, Mongan J, Ray KM, Hayward JH, Kelil T, Sieberg R, Hylton N, Joe BN, Lee AY -
Safety and efficacy of HSP90 inhibitor ganetespib for neoadjuvant treatment of stage II/III breast cancer.
NPJ breast cancer 2022 Lang JE, Forero-Torres A, Yee D, Yau C, Wolf D, Park J, Parker BA, Chien AJ, Wallace AM, Murthy R, Albain KS, Ellis ED, Beckwith H, Haley BB, Elias AD, Boughey JC, Yung RL, Isaacs C, Clark AS, Han HS,… -
Deep Learning to Simulate Contrast-enhanced Breast MRI of Invasive Breast Cancer.
Radiology 2022 Chung M, Calabrese E, Mongan J, Ray KM, Hayward JH, Kelil T, Sieberg R, Hylton N, Joe BN, Lee AY -
Diffusion-Weighted MRI for Predicting Pathologic Complete Response in Neoadjuvant Immunotherapy.
Cancers 2022 Li W, Le NN, Onishi N, Newitt DC, Wilmes LJ, Gibbs JE, Carmona-Bozo J, Liang J, Partridge SC, Price ER, Joe BN, Kornak J, Magbanua MJM, Nanda R, LeStage B, Esserman LJ, Van't Veer LJ, Hylton NM -
Expert tumor annotations and radiomics for locally advanced breast cancer in DCE-MRI for ACRIN 6657/I-SPY1.
Scientific data 2022 Chitalia R, Pati S, Bhalerao M, Thakur SP, Jahani N, Belenky V, McDonald ES, Gibbs J, Newitt DC, Hylton NM, Kontos D, Bakas S -
Redefining breast cancer subtypes to guide treatment prioritization and maximize response: Predictive biomarkers across 10 cancer therapies.
Cancer cell 2022 Wolf DM, Yau C, Wulfkuhle J, Brown-Swigart L, Gallagher RI, Lee PRE, Zhu Z, Magbanua MJ, Sayaman R, O'Grady N, Basu A, Delson A, Coppé JP, Lu R, Braun J, I-SPY2 Investigators, Asare SM, Sit L, … -
Effect of Inter-Reader Variability on Diffusion-Weighted MRI Apparent Diffusion Coefficient Measurements and Prediction of Pathologic Complete Response for Breast Cancer.
Tomography (Ann Arbor, Mich.) 2022 Le NN, Li W, Onishi N, Newitt DC, Gibbs JE, Wilmes LJ, Kornak J, Partridge SC, LeStage B, Price ER, Joe BN, Esserman LJ, Hylton NM -
Impact of deformable registration methods for prediction of recurrence free survival response to neoadjuvant chemotherapy in breast cancer: Results from the ISPY 1/ACRIN 6657 trial.
Translational oncology 2022 Thakran S, Cohen E, Jahani N, Weinstein SP, Pantalone L, Hylton N, Newitt D, DeMichele A, Davatzikos C, Kontos D -
Post-Processing Bias Field Inhomogeneity Correction for Assessing Background Parenchymal Enhancement on Breast MRI as a Quantitative Marker of Treatment Response.
Tomography (Ann Arbor, Mich.) 2022 Nguyen AA, Onishi N, Carmona-Bozo J, Li W, Kornak J, Newitt DC, Hylton NM -
Impact of Alternate b-Value Combinations and Metrics on the Predictive Performance and Repeatability of Diffusion-Weighted MRI in Breast Cancer Treatment: Results from the ECOG-ACRIN A6698 Trial.
Tomography (Ann Arbor, Mich.) 2022 Partridge SC, Steingrimsson J, Newitt DC, Gibbs JE, Marques HS, Bolan PJ, Boss MA, Chenevert TL, Rosen MA, Hylton NM -
Neoadjuvant T-DM1/pertuzumab and paclitaxel/trastuzumab/pertuzumab for HER2+ breast cancer in the adaptively randomized I-SPY2 trial.
Nature communications 2021 Clark AS, Yau C, Wolf DM, Petricoin EF, van 't Veer LJ, Yee D, Moulder SL, Wallace AM, Chien AJ, Isaacs C, Boughey JC, Albain KS, Kemmer K, Haley BB, Han HS, Forero-Torres A, Elias A, Lang JE, Ellis … -
Assessment of Residual Cancer Burden and Event-Free Survival in Neoadjuvant Treatment for High-risk Breast Cancer: An Analysis of Data From the I-SPY2 Randomized Clinical Trial.
JAMA oncology 2021 Symmans WF, Yau C, Chen YY, Balassanian R, Klein ME, Pusztai L, Nanda R, Parker BA, Datnow B, Krings G, Wei S, Feldman MD, Duan X, Chen B, Sattar H, Khazai L, Zeck JC, Sams S, Mhawech-Fauceglia P, … -
Ganitumab and metformin plus standard neoadjuvant therapy in stage 2/3 breast cancer.
NPJ breast cancer 2021 Yee D, Isaacs C, Wolf DM, Yau C, Haluska P, Giridhar KV, Forero-Torres A, Jo Chien A, Wallace AM, Pusztai L, Albain KS, Ellis ED, Beckwith H, Haley BB, Elias AD, Boughey JC, Kemmer K, Yung RL, … -
18F-FDG PET/CT Predicts Response to HER2-directed Neoadjuvant Therapy.
Radiology. Imaging cancer 2021 Diwanji D, Ray K, Hylton N -
Breast MRI during Neoadjuvant Chemotherapy: Lack of Background Parenchymal Enhancement Suppression and Inferior Treatment Response.
Radiology 2021 Onishi N, Li W, Newitt DC, Harnish RJ, Strand F, Nguyen AA, Arasu VA, Gibbs J, Jones EF, Wilmes LJ, Kornak J, Joe BN, Price ER, Ojeda-Fournier H, Eghtedari M, Zamora KW, Woodard S, Umphrey HR, Nelson … -
Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 trial.
Cancer cell 2021 Pusztai L, Yau C, Wolf DM, Han HS, Du L, Wallace AM, String-Reasor E, Boughey JC, Chien AJ, Elias AD, Beckwith H, Nanda R, Albain KS, Clark AS, Kemmer K, Kalinsky K, Isaacs C, Thomas A, Shatsky R, … -
Modulation of the immune microenvironment of high-risk ductal carcinoma in situ by intralesional pembrolizumab injection.
NPJ breast cancer 2021 Glencer AC, Wong JM, Hylton NM, Krings G, McCune E, Rothschild HT, Loveday TA, Alvarado MD, Esserman LJ, Campbell MJ -
Mask-Guided Convolutional Neural Network for Breast Tumor Prognostic Outcome Prediction on 3D DCE-MR Images.
Journal of digital imaging 2021 Liu G, Mitra D, Jones EF, Franc BL, Behr SC, Nguyen A, Bolouri MS, Wisner DJ, Joe BN, Esserman LJ, Hylton NM, Seo Y -
Circulating tumor DNA and magnetic resonance imaging to predict neoadjuvant chemotherapy response and recurrence risk.
NPJ breast cancer 2021 Magbanua MJM, Li W, Wolf DM, Yau C, Hirst GL, Swigart LB, Newitt DC, Gibbs J, Delson AL, Kalashnikova E, Aleshin A, Zimmermann B, Chien AJ, Tripathy D, Esserman L, Hylton N, van 't Veer L -
Accuracy of breast MRI in evaluating nodal status after neoadjuvant therapy in invasive lobular carcinoma.
NPJ breast cancer 2021 Abel MK, Greenwood H, Kelil T, Guo R, Brabham C, Hylton N, Wong J, Alvarado M, Ewing C, Esserman LJ, Boughey JC, Mukhtar RA -
The Way of the Future: Personalizing Treatment Plans Through Technology.
American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting 2021 Liefaard MC, Lips EH, Wesseling J, Hylton NM, Lou B, Mansi T, Pusztai L -
Predicted sensitivity to endocrine therapy for stage II-III hormone receptor-positive and HER2-negative (HR+/HER2-) breast cancer before chemo-endocrine therapy.
Annals of oncology : official journal of the European Society for Medical Oncology 2021 Du L, Yau C, Brown-Swigart L, Gould R, Krings G, Hirst GL, Bedrosian I, Layman RM, Carter JM, Klein M, Venters S, Shad S, van der Noordaa M, Chien AJ, Haddad T, Isaacs C, Pusztai L, Albain K, Nanda R,… -
Factors Affecting Image Quality and Lesion Evaluability in Breast Diffusion-weighted MRI: Observations from the ECOG-ACRIN Cancer Research Group Multisite Trial (A6702).
Journal of breast imaging 2020 Whisenant JG, Romanoff J, Rahbar H, Kitsch AE, Harvey SM, Moy L, DeMartini WB, Dogan BE, Yang WT, Wang LC, Joe BN, Wilmes LJ, Hylton NM, Oh KY, Tudorica LA, Neal CH, Malyarenko DI, McDonald ES, … -
Evaluation of primary breast cancers using dedicated breast PET and whole-body PET.
Scientific reports 2020 Hathi DK, Li W, Seo Y, Flavell RR, Kornak J, Franc BL, Joe BN, Esserman LJ, Hylton NM, Jones EF -
Predicting breast cancer response to neoadjuvant treatment using multi-feature MRI: results from the I-SPY 2 TRIAL.
NPJ breast cancer 2020 Li W, Newitt DC, Gibbs J, Wilmes LJ, Jones EF, Arasu VA, Strand F, Onishi N, Nguyen AA, Kornak J, Joe BN, Price ER, Ojeda-Fournier H, Eghtedari M, Zamora KW, Woodard SA, Umphrey H, Bernreuter W, … -
Mean Apparent Diffusion Coefficient Is a Sufficient Conventional Diffusion-weighted MRI Metric to Improve Breast MRI Diagnostic Performance: Results from the ECOG-ACRIN Cancer Research Group A6702 Diffusion Imaging Trial.
Radiology 2020 McDonald ES, Romanoff J, Rahbar H, Kitsch AE, Harvey SM, Whisenant JG, Yankeelov TE, Moy L, DeMartini WB, Dogan BE, Yang WT, Wang LC, Joe BN, Wilmes LJ, Hylton NM, Oh KY, Tudorica LA, Neal CH, … -
Association of Event-Free and Distant Recurrence-Free Survival With Individual-Level Pathologic Complete Response in Neoadjuvant Treatment of Stages 2 and 3 Breast Cancer: Three-Year Follow-up Analysis for the I-SPY2 Adaptively Randomized Clinical Trial.
JAMA oncology 2020 I-SPY2 Trial Consortium, Yee D, DeMichele AM, Yau C, Isaacs C, Symmans WF, Albain KS, Chen YY, Krings G, Wei S, Harada S, Datnow B, Fadare O, Klein M, Pambuccian S, Chen B, Adamson K, Sams S, Mhawech-… -
Predictive Value of Breast MRI Background Parenchymal Enhancement for Neoadjuvant Treatment Response among HER2- Patients.
Journal of breast imaging 2020 Arasu VA, Kim P, Li W, Strand F, McHargue C, Harnish R, Newitt DC, Jones EF, Glymour MM, Kornak J, Esserman LJ, Hylton NM, ISPY2 investigators -
Denoising and Multiple Tissue Compartment Visualization of Multi-b-Valued Breast Diffusion MRI.
Journal of magnetic resonance imaging : JMRI 2020 Tan ET, Wilmes LJ, Joe BN, Onishi N, Arasu VA, Hylton NM, Marinelli L, Newitt DC -
Current Landscape of Breast Cancer Imaging and Potential Quantitative Imaging Markers of Response in ER-Positive Breast Cancers Treated with Neoadjuvant Therapy.
Cancers 2020 Jones EF, Hathi DK, Freimanis R, Mukhtar RA, Chien AJ, Esserman LJ, Van't Veer LJ, Joe BN, Hylton NM -
Comparison of Segmentation Methods in Assessing Background Parenchymal Enhancement as a Biomarker for Response to Neoadjuvant Therapy.
Tomography (Ann Arbor, Mich.) 2020 Nguyen AA, Arasu VA, Strand F, Li W, Onishi N, Gibbs J, Jones EF, Joe BN, Esserman LJ, Newitt DC, Hylton NM -
Impact of MRI Protocol Adherence on Prediction of Pathological Complete Response in the I-SPY 2 Neoadjuvant Breast Cancer Trial.
Tomography (Ann Arbor, Mich.) 2020 Onishi N, Li W, Gibbs J, Wilmes LJ, Nguyen A, Jones EF, Arasu V, Kornak J, Joe BN, Esserman LJ, Newitt DC, Hylton NM -
Repeatability and Reproducibility of ADC Histogram Metrics from the ACRIN 6698 Breast Cancer Therapy Response Trial.
Tomography (Ann Arbor, Mich.) 2020 Newitt DC, Amouzandeh G, Partridge SC, Marques HS, Herman BA, Ross BD, Hylton NM, Chenevert TL, Malyarenko DI -
Retrospective Correction of ADC for Gradient Nonlinearity Errors in Multicenter Breast DWI Trials: ACRIN6698 Multiplatform Feasibility Study.
Tomography (Ann Arbor, Mich.) 2020 Malyarenko DI, Newitt DC, Amouzandeh G, Wilmes LJ, Tan ET, Marinelli L, Devaraj A, Peeters JM, Giri S, Vom Endt A, Hylton NM, Partridge SC, Chenevert TL -
Tumor Sphericity Predicts Response in Neoadjuvant Chemotherapy for Invasive Breast Cancer.
Tomography (Ann Arbor, Mich.) 2020 Li W, Newitt DC, Yun B, Jones EF, Arasu V, Wilmes LJ, Gibbs J, Nguyen AA, Onishi N, Kornak J, Joe BN, Esserman LJ, Hylton NM -
Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer: An Analysis of the Ongoing Phase 2 Adaptively Randomized I-SPY2 Trial.
JAMA oncology 2020 Nanda R, Liu MC, Yau C, Shatsky R, Pusztai L, Wallace A, Chien AJ, Forero-Torres A, Ellis E, Han H, Clark A, Albain K, Boughey JC, Jaskowiak NT, Elias A, Isaacs C, Kemmer K, Helsten T, Majure M, … -
Phase II Single-Arm Study of Preoperative Letrozole for Estrogen Receptor-Positive Postmenopausal Ductal Carcinoma In Situ: CALGB 40903 (Alliance).
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2020 Hwang ES, Hyslop T, Hendrix LH, Duong S, Bedrosian I, Price E, Caudle A, Hieken T, Guenther J, Hudis CA, Winer E, Lyss AP, Dickson-Witmer D, Hoefer R, Ollila DW, Hardman T, Marks J, Chen YY, Krings G,… -
Pubertal timing and breast density in young women: a prospective cohort study.
Breast cancer research : BCR 2019 Houghton LC, Jung S, Troisi R, LeBlanc ES, Snetselaar LG, Hylton NM, Klifa C, Van Horn L, Paris K, Shepherd JA, Hoover RN, Dorgan JF -
Complete Breast MRI Response to Neoadjuvant Chemotherapy and Prediction of Pathologic Complete Response.
Journal of breast imaging 2019 Chen CA, Hayward JH, Woodard GA, Ray KM, Starr CJ, Hylton NM, Joe BN, Lee AY -
Prediction of Treatment Response to Neoadjuvant Chemotherapy for Breast Cancer via Early Changes in Tumor Heterogeneity Captured by DCE-MRI Registration.
Scientific reports 2019 Jahani N, Cohen E, Hsieh MK, Weinstein SP, Pantalone L, Hylton N, Newitt D, Davatzikos C, Kontos D -
Additive value of diffusion-weighted MRI in the I-SPY 2 TRIAL.
Journal of magnetic resonance imaging : JMRI 2019 Li W, Newitt DC, Wilmes LJ, Jones EF, Arasu V, Gibbs J, La Yun B, Li E, Partridge SC, Kornak J, I-SPY 2 Consortium, Esserman LJ, Hylton NM -
Initial experience of dedicated breast PET imaging of ER+ breast cancers using [F-18]fluoroestradiol.
NPJ breast cancer 2019 Jones EF, Ray KM, Li W, Chien AJ, Mukhtar RA, Esserman LJ, Franc BL, Seo Y, Pampaloni MH, Joe BN, Hylton NM -
Diffusion-weighted MRI in Multicenter Trials of Breast Cancer.
Radiology 2019 Partridge SC, Newitt DC, Chenevert TL, Rosen MA, Hylton NM, ACRIN 6698 Trial Team and I-SPY 2 Trial Investigators -
MK-2206 and Standard Neoadjuvant Chemotherapy Improves Response in Patients With Human Epidermal Growth Factor Receptor 2-Positive and/or Hormone Receptor-Negative Breast Cancers in the I-SPY 2 Trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2019 Chien AJ, Tripathy D, Albain KS, Symmans WF, Rugo HS, Melisko ME, Wallace AM, Schwab R, Helsten T, Forero-Torres A, Stringer-Reasor E, Ellis ED, Kaplan HG, Nanda R, Jaskowiak N, Murthy R, Godellas C, … -
Test-retest repeatability and reproducibility of ADC measures by breast DWI: Results from the ACRIN 6698 trial.
Journal of magnetic resonance imaging : JMRI 2018 Newitt DC, Zhang Z, Gibbs JE, Partridge SC, Chenevert TL, Rosen MA, Bolan PJ, Marques HS, Aliu S, Li W, Cimino L, Joe BN, Umphrey H, Ojeda-Fournier H, Dogan B, Oh K, Abe H, Drukteinis J, Esserman LJ, … -
Tissue oxygen saturation predicts response to breast cancer neoadjuvant chemotherapy within 10 days of treatment.
Journal of biomedical optics 2018 Cochran JM, Busch DR, Leproux A, Zhang Z, O'Sullivan TD, Cerussi AE, Carpenter PM, Mehta RS, Roblyer D, Yang W, Paulsen KD, Pogue B, Jiang S, Kaufman PA, Chung SH, Schnall M, Snyder BS, Hylton N, Carp… -
Diffusion-weighted MRI Findings Predict Pathologic Response in Neoadjuvant Treatment of Breast Cancer: The ACRIN 6698 Multicenter Trial.
Radiology 2018 Partridge SC, Zhang Z, Newitt DC, Gibbs JE, Chenevert TL, Rosen MA, Bolan PJ, Marques HS, Romanoff J, Cimino L, Joe BN, Umphrey HR, Ojeda-Fournier H, Dogan B, Oh K, Abe H, Drukteinis JS, Esserman LJ, … -
Residual Disease after Neoadjuvant Therapy for Breast Cancer: Can MRI Help?
Radiology 2018 Hylton NM -
Evaluation of the HER/PI3K/AKT Family Signaling Network as a Predictive Biomarker of Pathologic Complete Response for Patients With Breast Cancer Treated With Neratinib in the I-SPY 2 TRIAL.
JCO precision oncology 2018 Wulfkuhle JD, Yau C, Wolf DM, Vis DJ, Gallagher RI, Brown-Swigart L, Hirst G, Voest EE, DeMichele A, Hylton N, Symmans F, Yee D, Esserman L, Berry D, Liu M, Park JW, Wessels LFA, Van't Veer L, … -
Exploration of PET and MRI radiomic features for decoding breast cancer phenotypes and prognosis.
NPJ breast cancer 2018 Huang SY, Franc BL, Harnish RJ, Liu G, Mitra D, Copeland TP, Arasu VA, Kornak J, Jones EF, Behr SC, Hylton NM, Price ER, Esserman L, Seo Y -
The Use of Quantitative Imaging in Radiation Oncology: A Quantitative Imaging Network (QIN) Perspective.
International journal of radiation oncology, biology, physics 2018 Press RH, Shu HG, Shim H, Mountz JM, Kurland BF, Wahl RL, Jones EF, Hylton NM, Gerstner ER, Nordstrom RJ, Henderson L, Kurdziel KA, Vikram B, Jacobs MA, Holdhoff M, Taylor E, Jaffray DA, Schwartz LH, … -
Intake of dietary carbohydrates in early adulthood and adolescence and breast density among young women.
Cancer causes & control : CCC 2018 Jung S, Goloubeva O, Hylton N, Klifa C, LeBlanc E, Shepherd J, Snetselaar L, Van Horn L, Dorgan JF -
MRI, Clinical Examination, and Mammography for Preoperative Assessment of Residual Disease and Pathologic Complete Response After Neoadjuvant Chemotherapy for Breast Cancer: ACRIN 6657 Trial.
AJR. American journal of roentgenology 2018 Scheel JR, Kim E, Partridge SC, Lehman CD, Rosen MA, Bernreuter WK, Pisano ED, Marques HS, Morris EA, Weatherall PT, Polin SM, Newstead GM, Esserman LJ, Schnall MD, Hylton NM, ACRIN 6657 Trial Team … -
Features of MRI stromal enhancement with neoadjuvant chemotherapy: a subgroup analysis of the ACRIN 6657/I-SPY TRIAL.
Journal of medical imaging (Bellingham, Wash.) 2017 Olshen A, Wolf D, Jones EF, Newitt D, van ‘t Veer LJ, Yau C, Esserman L, Wulfkuhle JD, Gallagher RI, Singer L, Petricoin EF, Hylton N, Park CC -
Effect of Background Parenchymal Enhancement on Breast MR Imaging Interpretive Performance in Community-based Practices.
Radiology 2017 Ray KM, Kerlikowske K, Lobach IV, Hofmann MB, Greenwood HI, Arasu VA, Hylton NM, Joe BN -
Multisite concordance of apparent diffusion coefficient measurements across the NCI Quantitative Imaging Network.
Journal of medical imaging (Bellingham, Wash.) 2017 Newitt DC, Malyarenko D, Chenevert TL, Quarles CC, Bell L, Fedorov A, Fennessy F, Jacobs MA, Solaiyappan M, Hectors S, Taouli B, Muzi M, Kinahan PE, Schmainda KM, Prah MA, Taber EN, Kroenke C, Huang W… -
Accuracy, repeatability, and interplatform reproducibility of T1 quantification methods used for DCE-MRI: Results from a multicenter phantom study.
Magnetic resonance in medicine 2017 Bane O, Hectors SJ, Wagner M, Arlinghaus LL, Aryal MP, Cao Y, Chenevert TL, Fennessy F, Huang W, Hylton NM, Kalpathy-Cramer J, Keenan KE, Malyarenko DI, Mulkern RV, Newitt DC, Russek SE, Stupic KF, … -
DNA repair deficiency biomarkers and the 70-gene ultra-high risk signature as predictors of veliparib/carboplatin response in the I-SPY 2 breast cancer trial.
NPJ breast cancer 2017 Wolf DM, Yau C, Sanil A, Glas A, Petricoin E, Wulfkuhle J, Severson TM, Linn S, Brown-Swigart L, Hirst G, Buxton M, DeMichele A, Hylton N, Symmans F, Yee D, Paoloni M, Esserman L, Berry D, Rugo H, … -
Performance assessment of diffuse optical spectroscopic imaging instruments in a 2-year multicenter breast cancer trial
Journal of biomedical optics 2017 O'Sullivan TD, Cerussi A, Durkin A, Hill B, Hylton N, Yodh AG, Carp SA, Boas D, Jiang S, Paulsen KD, Pogue B, Roblyer D, Yang W, Tromberg BJ -
Dedicated Breast Positron Emission Tomography for the Evaluation of Early Response to Neoadjuvant Chemotherapy in Breast Cancer.
Clinical breast cancer 2016 Jones EF, Ray KM, Li W, Seo Y, Franc BL, Chien AJ, Esserman LJ, Pampaloni MH, Joe BN, Hylton NM -
MR spectroscopy of breast cancer for assessing early treatment response: Results from the ACRIN 6657 MRS trial.
Journal of magnetic resonance imaging : JMRI 2016 Bolan PJ, Kim E, Herman BA, Newstead GM, Rosen MA, Schnall MD, Pisano ED, Weatherall PT, Morris EA, Lehman CD, Garwood M, Nelson MT, Yee D, Polin SM, Esserman LJ, Gatsonis CA, Metzger GJ, Newitt DC, … -
Computational Challenges and Collaborative Projects in the NCI Quantitative Imaging Network.
Tomography (Ann Arbor, Mich.) 2016 Farahani K, Kalpathy-Cramer J, Chenevert TL, Rubin DL, Sunderland JJ, Nordstrom RJ, Buatti J, Hylton N -
Diffusion Tensor Imaging for Assessment of Response to Neoadjuvant Chemotherapy in Patients With Breast Cancer.
Tomography (Ann Arbor, Mich.) 2016 Wilmes LJ, Li W, Shin HJ, Newitt DC, Proctor E, Harnish R, Hylton NM -
Effect of MR Imaging Contrast Thresholds on Prediction of Neoadjuvant Chemotherapy Response in Breast Cancer Subtypes: A Subgroup Analysis of the ACRIN 6657/I-SPY 1 TRIAL.
Tomography (Ann Arbor, Mich.) 2016 Li W, Arasu V, Newitt DC, Jones EF, Wilmes L, Gibbs J, Kornak J, Joe BN, Esserman LJ, Hylton NM, ACRIN 6657 Trial Team and I-SPY Investigators Network -
Predicting Responses to Neoadjuvant Chemotherapy in Breast Cancer: ACRIN 6691 Trial of Diffuse Optical Spectroscopic Imaging.
Cancer research 2016 Tromberg BJ, Zhang Z, Leproux A, O'Sullivan TD, Cerussi AE, Carpenter PM, Mehta RS, Roblyer D, Yang W, Paulsen KD, Pogue BW, Jiang S, Kaufman PA, Yodh AG, Chung SH, Schnall M, Snyder BS, Hylton N, … -
Adaptive Randomization of Neratinib in Early Breast Cancer.
The New England journal of medicine 2016 Park JW, Liu MC, Yee D, Yau C, van 't Veer LJ, Symmans WF, Paoloni M, Perlmutter J, Hylton NM, Hogarth M, DeMichele A, Buxton MB, Chien AJ, Wallace AM, Boughey JC, Haddad TC, Chui SY, Kemmer KA, … -
Adaptive Randomization of Veliparib-Carboplatin Treatment in Breast Cancer.
The New England journal of medicine 2016 Rugo HS, Olopade OI, DeMichele A, Yau C, van 't Veer LJ, Buxton MB, Hogarth M, Hylton NM, Paoloni M, Perlmutter J, Symmans WF, Yee D, Chien AJ, Wallace AM, Kaplan HG, Boughey JC, Haddad TC, Albain KS,… -
Early Life Body Fatness, Serum Anti-Müllerian Hormone, and Breast Density in Young Adult Women.
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2016 Bertrand KA, Baer HJ, Orav EJ, Klifa C, Kumar A, Hylton NM, LeBlanc ES, Snetselaar LG, Van Horn L, Dorgan JF -
Variability and bias assessment in breast ADC measurement across multiple systems.
Journal of magnetic resonance imaging : JMRI 2016 Keenan KE, Peskin AP, Wilmes LJ, Aliu SO, Jones EF, Li W, Kornak J, Newitt DC, Hylton NM -
Design of a breast phantom for quantitative MRI.
Journal of magnetic resonance imaging : JMRI 2016 Keenan KE, Wilmes LJ, Aliu SO, Newitt DC, Jones EF, Boss MA, Stupic KF, Russek SE, Hylton NM -
Effect of Imaging Parameter Thresholds on MRI Prediction of Neoadjuvant Chemotherapy Response in Breast Cancer Subtypes.
PloS one 2016 Lo WC, Li W, Jones EF, Newitt DC, Kornak J, Wilmes LJ, Esserman LJ, Hylton NM -
Quantitative Imaging in Cancer Clinical Trials.
Clinical cancer research : an official journal of the American Association for Cancer Research 2016 Yankeelov TE, Mankoff DA, Schwartz LH, Lieberman FS, Buatti JM, Mountz JM, Erickson BJ, Fennessy FM, Huang W, Kalpathy-Cramer J, Wahl RL, Linden HM, Kinahan PE, Zhao B, Hylton NM, Gillies RJ, Clarke L… -
Neoadjuvant Chemotherapy for Breast Cancer: Functional Tumor Volume by MR Imaging Predicts Recurrence-free Survival-Results from the ACRIN 6657/CALGB 150007 I-SPY 1 TRIAL.
Radiology 2015 Hylton NM, Gatsonis CA, Rosen MA, Lehman CD, Newitt DC, Partridge SC, Bernreuter WK, Pisano ED, Morris EA, Weatherall PT, Polin SM, Newstead GM, Marques HS, Esserman LJ, Schnall MD, ACRIN 6657 Trial … -
Body fatness during childhood and adolescence and breast density in young women: a prospective analysis.
Breast cancer research : BCR 2015 Bertrand KA, Baer HJ, Orav EJ, Klifa C, Shepherd JA, Van Horn L, Snetselaar L, Stevens VJ, Hylton NM, Dorgan JF -
How to use magnetic resonance imaging following neoadjuvant chemotherapy in locally advanced breast cancer.
World journal of clinical cases 2015 Price ER, Wong J, Mukhtar R, Hylton N, Esserman LJ -
Adolescent endogenous sex hormones and breast density in early adulthood.
Breast cancer research : BCR 2015 Jung S, Egleston BL, Chandler DW, Van Horn L, Hylton NM, Klifa CC, Lasser NL, LeBlanc ES, Paris K, Shepherd JA, Snetselaar LG, Stanczyk FZ, Stevens VJ, Dorgan JF -
Multi-site clinical evaluation of DW-MRI as a treatment response metric for breast cancer patients undergoing neoadjuvant chemotherapy.
PloS one 2015 Galbán CJ, Ma B, Malyarenko D, Pickles MD, Heist K, Henry NL, Schott AF, Neal CH, Hylton NM, Rehemtulla A, Johnson TD, Meyer CR, Chenevert TL, Turnbull LW, Ross BD -
Gradient nonlinearity correction to improve apparent diffusion coefficient accuracy and standardization in the american college of radiology imaging network 6698 breast cancer trial.
Journal of magnetic resonance imaging : JMRI 2015 Newitt DC, Tan ET, Wilmes LJ, Chenevert TL, Kornak J, Marinelli L, Hylton N -
Extra-mammary findings on breast MRI: a pictorial review.
Clinical imaging 2015 Karp NL, Price ER, Wisner DJ, Chang CB, Hylton NM, Joe BN -
The Neoadjuvant Model Is Still the Future for Drug Development in Breast Cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2015 DeMichele A, Yee D, Berry DA, Albain KS, Benz CC, Boughey J, Buxton M, Chia SK, Chien AJ, Chui SY, Clark A, Edmiston K, Elias AD, Forero-Torres A, Haddad TC, Haley B, Haluska P, Hylton NM, Isaacs C, … -
Lesion morphology on breast MRI affects targeted ultrasound correlation rate.
European radiology 2014 Hollowell L, Price E, Arasu V, Wisner D, Hylton N, Joe B -
Imaging features of HER2 overexpression in breast cancer: a systematic review and meta-analysis.
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2014 Elias SG, Adams A, Wisner DJ, Esserman LJ, van't Veer LJ, Mali WP, Gilhuijs KG, Hylton NM -
Errors in Quantitative Image Analysis due to Platform-Dependent Image Scaling.
Translational oncology 2014 Chenevert TL, Malyarenko DI, Newitt D, Li X, Jayatilake M, Tudorica A, Fedorov A, Kikinis R, Liu TT, Muzi M, Oborski MJ, Laymon CM, Li X, Thomas Y, Jayashree KC, Mountz JM, Kinahan PE, Rubin DL, … -
Image registration for quantitative parametric response mapping of cancer treatment response.
Translational oncology 2014 Boes JL, Hoff BA, Hylton N, Pickles MD, Turnbull LW, Schott AF, Rehemtulla A, Chamberlain R, Lemasson B, Chenevert TL, Galbán CJ, Meyer CR, Ross BD -
Real-Time Measurement of Functional Tumor Volume by MRI to Assess Treatment Response in Breast Cancer Neoadjuvant Clinical Trials: Validation of the Aegis SER Software Platform.
Translational oncology 2014 Newitt DC, Aliu SO, Witcomb N, Sela G, Kornak J, Esserman L, Hylton NM -
Repeatability of quantitative MRI measurements in normal breast tissue.
Translational oncology 2014 Aliu SO, Jones EF, Azziz A, Kornak J, Wilmes LJ, Newitt DC, Suzuki SA, Klifa C, Gibbs J, Proctor EC, Joe BN, Hylton NM -
Optimized breast MRI functional tumor volume as a biomarker of recurrence-free survival following neoadjuvant chemotherapy.
Journal of magnetic resonance imaging : JMRI 2013 Jafri NF, Newitt DC, Kornak J, Esserman LJ, Joe BN, Hylton NM -
Agreement of mammographic measures of volumetric breast density to MRI.
PloS one 2013 Wang J, Azziz A, Fan B, Malkov S, Klifa C, Newitt D, Yitta S, Hylton N, Kerlikowske K, Shepherd JA -
High-resolution diffusion-weighted imaging for the separation of benign from malignant BI-RADS 4/5 lesions found on breast MRI at 3T.
Journal of magnetic resonance imaging : JMRI 2013 Wisner DJ, Rogers N, Deshpande VS, Newitt DN, Laub GA, Porter DA, Kornak J, Joe BN, Hylton NM -
Features of occult invasion in biopsy-proven DCIS at breast MRI.
The breast journal 2013 Wisner DJ, Hwang ES, Chang CB, Tso HH, Joe BN, Lessing JN, Lu Y, Hylton NM -
High resolution in vivo characterization of apparent diffusion coefficient at the tumor-stromal boundary of breast carcinomas: a pilot study to assess treatment response using proximity-dependent diffusion-weighted imaging.
Journal of magnetic resonance imaging : JMRI 2013 McLaughlin RL, Newitt DC, Wilmes LJ, Jones EF, Wisner DJ, Kornak J, Proctor E, Joe BN, Hylton NM -
Menstrual and reproductive characteristics and breast density in young women.
Cancer causes & control : CCC 2013 Dorgan JF, Klifa C, Deshmukh S, Egleston BL, Shepherd JA, Kwiterovich PO, Van Horn L, Snetselaar LG, Stevens VJ, Robson AM, Lasser NL, Hylton NM -
Breast magnetic resonance imaging for monitoring response to therapy.
Magnetic resonance imaging clinics of North America 2013 Ojeda-Fournier H, de Guzman J, Hylton N -
Triple-negative and non-triple-negative invasive breast cancer: association between MR and fluorine 18 fluorodeoxyglucose PET imaging.
Radiology 2013 Bolouri MS, Elias SG, Wisner DJ, Behr SC, Hawkins RA, Suzuki SA, Banfield KS, Joe BN, Hylton NM -
Clinically meaningful tumor reduction rates vary by prechemotherapy MRI phenotype and tumor subtype in the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657).
Annals of surgical oncology 2013 Mukhtar RA, Yau C, Rosen M, Tandon VJ, I-SPY 1 TRIAL and ACRIN 6657 Investigators, Hylton N, Esserman LJ -
Accuracy and interpretation time of computer-aided detection among novice and experienced breast MRI readers.
AJR. American journal of roentgenology 2013 Lehman CD, Blume JD, DeMartini WB, Hylton NM, Herman B, Schnall MD -
Recognizing artifacts and optimizing breast MRI at 1.5 and 3 T.
AJR. American journal of roentgenology 2013 Yitta S, Joe BN, Wisner DJ, Price ER, Hylton NM -
Intraductal therapy of ductal carcinoma in situ: a presurgery study.
Clinical breast cancer 2013 Mahoney ME, Gordon EJ, Rao JY, Jin Y, Hylton N, Love SM -
MRI enhancement in stromal tissue surrounding breast tumors: association with recurrence free survival following neoadjuvant chemotherapy.
PloS one 2013 Jones EF, Sinha SP, Newitt DC, Klifa C, Kornak J, Park CC, Hylton NM -
High-resolution diffusion-weighted imaging for monitoring breast cancer treatment response.
Academic radiology 2013 Wilmes LJ, McLaughlin RL, Newitt DC, Singer L, Sinha SP, Proctor E, Wisner DJ, Saritas EU, Kornak J, Shankaranarayanan A, Banerjee S, Jones EF, Joe BN, Hylton NM -
Magnetic resonance imaging as a predictor of pathologic response in patients treated with neoadjuvant systemic treatment for operable breast cancer. Translational Breast Cancer Research Consortium trial 017.
Cancer 2013 De Los Santos JF, Cantor A, Amos KD, Forero A, Golshan M, Horton JK, Hudis CA, Hylton NM, McGuire K, Meric-Bernstam F, Meszoely IM, Nanda R, Hwang ES -
MR imaging for the prediction of breast cancer response to neoadjuvant chemotherapy.
Radiology 2013 Hylton N -
Height, adiposity and body fat distribution and breast density in young women.
Breast cancer research : BCR 2012 Dorgan JF, Klifa C, Shepherd JA, Egleston BL, Kwiterovich PO, Himes JH, Gabriel K, Horn L, Snetselaar LG, Stevens VJ, Barton BA, Robson AM, Lasser NL, Deshmukh S, Hylton NM -
A common language in neoadjuvant breast cancer clinical trials: proposals for standard definitions and endpoints.
The Lancet. Oncology 2012 Fumagalli D, Bedard PL, Nahleh Z, Michiels S, Sotiriou C, Loi S, Sparano JA, Ellis M, Hylton N, Zujewski JA, Hudis C, Esserman L, Piccart M, BIG-NABCG collaboration -
Locally advanced breast cancer: MR imaging for prediction of response to neoadjuvant chemotherapy--results from ACRIN 6657/I-SPY TRIAL.
Radiology 2012 Hylton NM, Blume JD, Bernreuter WK, Pisano ED, Rosen MA, Morris EA, Weatherall PT, Lehman CD, Newstead GM, Polin S, Marques HS, Esserman LJ, Schnall MD, ACRIN 6657 Trial Team and I-SPY 1 TRIAL … -
Pathologic complete response predicts recurrence-free survival more effectively by cancer subset: results from the I-SPY 1 TRIAL--CALGB 150007/150012, ACRIN 6657.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2012 Esserman LJ, Berry DA, DeMichele A, Carey L, Davis SE, Buxton M, Hudis C, Gray JW, Perou C, Yau C, Livasy C, Krontiras H, Montgomery L, Tripathy D, Lehman C, Liu MC, Olopade OI, Rugo HS, Carpenter JT,… -
Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657).
Breast cancer research and treatment 2011 Esserman LJ, Berry DA, Cheang MC, Yau C, Perou CM, Carey L, DeMichele A, Gray JW, Conway-Dorsey K, Lenburg ME, Buxton MB, Davis SE, van't Veer LJ, Hudis C, Chin K, Wolf D, Krontiras H, Montgomery L, … -
High-resolution diffusion-weighted magnetic resonance imaging in patients with locally advanced breast cancer.
Academic radiology 2011 Singer L, Wilmes LJ, Saritas EU, Shankaranarayanan A, Proctor E, Wisner DJ, Chang B, Joe BN, Nishimura DG, Hylton NM -
Diffusion-weighted MRI: influence of intravoxel fat signal and breast density on breast tumor conspicuity and apparent diffusion coefficient measurements.
Magnetic resonance imaging 2011 Partridge SC, Singer L, Sun R, Wilmes LJ, Klifa CS, Lehman CD, Hylton NM -
Outcome of long term active surveillance for estrogen receptor-positive ductal carcinoma in situ.
Breast (Edinburgh, Scotland) 2011 Meyerson AF, Lessing JN, Itakura K, Hylton NM, Wolverton DE, Joe BN, Esserman LJ, Hwang ES -
MRI in breast cancer therapy monitoring.
NMR in biomedicine 2011 McLaughlin R, Hylton N -
Quantitative tissue oxygen measurement in multiple organs using 19F MRI in a rat model.
Magnetic resonance in medicine 2011 Liu S, Shah SJ, Wilmes LJ, Feiner J, Kodibagkar VD, Wendland MF, Mason RP, Hylton N, Hopf HW, Rollins MD -
Quantification of background enhancement in breast magnetic resonance imaging.
Journal of magnetic resonance imaging : JMRI 2011 Klifa C, Suzuki S, Aliu S, Singer L, Wilmes L, Newitt D, Joe B, Hylton N -
MRI appearance of tumor recurrence in myocutaneous flap reconstruction after mastectomy.
AJR. American journal of roentgenology 2011 Peng C, Chang CB, Tso HH, Flowers CI, Hylton NM, Joe BN -
Can signal enhancement ratio (SER) reduce the number of recommended biopsies without affecting cancer yield in occult MRI-detected lesions?
Academic radiology 2011 Arasu VA, Chen RC, Newitt DN, Chang CB, Tso H, Hylton NM, Joe BN -
Topographic enhancement mapping of the cancer-associated breast stroma using breast MRI.
Integrative biology : quantitative biosciences from nano to macro 2011 Nabavizadeh N, Klifa C, Newitt D, Lu Y, Chen YY, Hsu H, Fisher C, Tokayasu T, Olshen AB, Spellman P, Gray JW, Hylton N, Park CC -
The impact of preoperative magnetic resonance imaging on surgical treatment and outcomes for ductal carcinoma in situ.
Clinical breast cancer 2011 Itakura K, Lessing J, Sakata T, Heinzerling A, Vriens E, Wisner D, Alvarado M, Esserman L, Ewing C, Hylton N, Hwang ES -
Adolescent diet and subsequent serum hormones, breast density, and bone mineral density in young women: results of the Dietary Intervention Study in Children follow-up study.
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2010 Dorgan JF, Liu L, Klifa C, Hylton N, Shepherd JA, Stanczyk FZ, Snetselaar LG, Van Horn L, Stevens VJ, Robson A, Kwiterovich PO, Lasser NL, Himes JH, Pettee Gabriel K, Kriska A, Ruder EH, Fang CY, … -
Role of breast MR imaging in neoadjuvant chemotherapy.
Magnetic resonance imaging clinics of North America 2010 Le-Petross HC, Hylton N -
Fluvastatin reduces proliferation and increases apoptosis in women with high grade breast cancer.
Breast cancer research and treatment 2010 Garwood ER, Kumar AS, Baehner FL, Moore DH, Au A, Hylton N, Flowers CI, Garber J, Lesnikoski BA, Hwang ES, Olopade O, Port ER, Campbell M, Esserman LJ -
A phase I study of a 2-day lapatinib chemosensitization pulse preceding nanoparticle albumin-bound Paclitaxel for advanced solid malignancies.
Clinical cancer research : an official journal of the American Association for Cancer Research 2009 Chien AJ, Illi JA, Ko AH, Korn WM, Fong L, Chen LM, Kashani-Sabet M, Ryan CJ, Rosenberg JE, Dubey S, Small EJ, Jahan TM, Hylton NM, Yeh BM, Huang Y, Koch KM, Moasser MM -
Can diffuse optical spectroscopic tomography be used to characterize breast lesions and their response to treatment?
Radiology 2009 Hylton NM -
Magnetic resonance imaging for secondary assessment of breast density in a high-risk cohort.
Magnetic resonance imaging 2009 Klifa C, Carballido-Gamio J, Wilmes L, Laprie A, Shepherd J, Gibbs J, Fan B, Noworolski S, Hylton N -
I-SPY 2: an adaptive breast cancer trial design in the setting of neoadjuvant chemotherapy.
Clinical pharmacology and therapeutics 2009 Barker AD, Sigman CC, Kelloff GJ, Hylton NM, Berry DA, Esserman LJ -
MRI methods for evaluating the effects of tyrosine kinase inhibitor administration used to enhance chemotherapy efficiency in a breast tumor xenograft model.
Journal of magnetic resonance imaging : JMRI 2009 Aliu SO, Wilmes LJ, Moasser MM, Hann BC, Li KL, Wang D, Hylton NM -
Ductal carcinoma in situ: state of the science and roadmap to advance the field.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008 Kuerer HM, Albarracin CT, Yang WT, Cardiff RD, Brewster AM, Symmans WF, Hylton NM, Middleton LP, Krishnamurthy S, Perkins GH, Babiera G, Edgerton ME, Czerniecki BJ, Arun BK, Hortobagyi GN -
Invasive breast cancer: predicting disease recurrence by using high-spatial-resolution signal enhancement ratio imaging.
Radiology 2008 Li KL, Partridge SC, Joe BN, Gibbs JE, Lu Y, Esserman LJ, Hylton NM -
Breast stromal enhancement on MRI is associated with response to neoadjuvant chemotherapy.
AJR. American journal of roentgenology 2008 Hattangadi J, Park C, Rembert J, Klifa C, Hwang J, Gibbs J, Hylton N -
Statement of the science concerning locoregional treatments after preoperative chemotherapy for breast cancer: a National Cancer Institute conference.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008 Buchholz TA, Lehman CD, Harris JR, Pockaj BA, Khouri N, Hylton NF, Miller MJ, Whelan T, Pierce LJ, Esserman LJ, Newman LA, Smith BL, Bear HD, Mamounas EP -
Improved tumor vascular function following high-dose epidermal growth factor receptor tyrosine kinase inhibitor therapy.
Journal of magnetic resonance imaging : JMRI 2007 Moasser MM, Wilmes LJ, Wong CH, Aliu S, Li KL, Wang D, Hom YK, Hann B, Hylton NM -
Kinetic assessment of breast tumors using high spatial resolution signal enhancement ratio (SER) imaging.
Magnetic resonance in medicine 2007 Li KL, Henry RG, Wilmes LJ, Gibbs J, Zhu X, Lu Y, Hylton NM -
AG-013736, a novel inhibitor of VEGF receptor tyrosine kinases, inhibits breast cancer growth and decreases vascular permeability as detected by dynamic contrast-enhanced magnetic resonance imaging.
Magnetic resonance imaging 2007 Wilmes LJ, Pallavicini MG, Fleming LM, Gibbs J, Wang D, Li KL, Partridge SC, Henry RG, Shalinsky DR, Hu-Lowe D, Park JW, McShane TM, Lu Y, Brasch RC, Hylton NM -
Characterization of breast lesions using the 3D FIESTA sequence and contrast-enhanced magnetic resonance imaging.
Journal of magnetic resonance imaging : JMRI 2007 Klifa CS, Shimakawa A, Siraj Z, Gibbs JE, Wilmes LJ, Partridge SC, Proctor E, Hylton NM -
Biologic significance of false-positive magnetic resonance imaging enhancement in the setting of ductal carcinoma in situ.
American journal of surgery 2006 Kumar AS, Chen DF, Au A, Chen YY, Leung J, Garwood ER, Gibbs J, Hylton N, Esserman LJ -
Magnetic resonance imaging captures the biology of ductal carcinoma in situ.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006 Esserman LJ, Kumar AS, Herrera AF, Leung J, Au A, Chen YY, Moore DH, Chen DF, Hellawell J, Wolverton D, Hwang ES, Hylton NM -
MR imaging for assessment of breast cancer response to neoadjuvant chemotherapy.
Magnetic resonance imaging clinics of North America 2006 Hylton N -
Dynamic contrast-enhanced magnetic resonance imaging as an imaging biomarker.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006 Hylton N -
Diagnostic architectural and dynamic features at breast MR imaging: multicenter study.
Radiology 2006 Schnall MD, Blume J, Bluemke DA, DeAngelis GA, DeBruhl N, Harms S, Heywang-Köbrunner SH, Hylton N, Kuhl CK, Pisano ED, Causer P, Schnitt SJ, Thickman D, Stelling CB, Weatherall PT, Lehman C, Gatsonis … -
Added cancer yield of MRI in screening the contralateral breast of women recently diagnosed with breast cancer: results from the International Breast Magnetic Resonance Consortium (IBMC) trial.
Journal of surgical oncology 2005 Lehman CD, Blume JD, Thickman D, Bluemke DA, Pisano E, Kuhl C, Julian TB, Hylton N, Weatherall P, O'loughlin M, Schnitt SJ, Gatsonis C, Schnall MD -
Heterogeneity in the angiogenic response of a BT474 human breast cancer to a novel vascular endothelial growth factor-receptor tyrosine kinase inhibitor: assessment by voxel analysis of dynamic contrast-enhanced MRI.
Journal of magnetic resonance imaging : JMRI 2005 Li KL, Wilmes LJ, Henry RG, Pallavicini MG, Park JW, Hu-Lowe DD, McShane TM, Shalinsky DR, Fu YJ, Brasch RC, Hylton NM -
MRI detection of distinct incidental cancer in women with primary breast cancer studied in IBMC 6883.
Journal of surgical oncology 2005 Schnall MD, Blume J, Bluemke DA, Deangelis GA, Debruhl N, Harms S, Heywang-Köbrunner SH, Hylton N, Kuhl CK, Pisano ED, Causer P, Schnitt SJ, Smazal SF, Stelling CB, Lehman C, Weatherall PT, Gatsonis … -
Combined diffuse optical spectroscopy and contrast-enhanced magnetic resonance imaging for monitoring breast cancer neoadjuvant chemotherapy: a case study.
Journal of biomedical optics 2005 Shah N, Gibbs J, Wolverton D, Cerussi A, Hylton N, Tromberg BJ -
MRI measurements of breast tumor volume predict response to neoadjuvant chemotherapy and recurrence-free survival.
AJR. American journal of roentgenology 2005 Partridge SC, Gibbs JE, Lu Y, Esserman LJ, Tripathy D, Wolverton DS, Rugo HS, Hwang ES, Ewing CA, Hylton NM -
Paget disease of the breast: findings at magnetic resonance imaging and histopathologic correlation.
Investigative radiology 2005 Frei KA, Bonel HM, Pelte MF, Hylton NM, Kinkel K -
Screening women at high risk for breast cancer with mammography and magnetic resonance imaging.
Cancer 2005 Lehman CD, Blume JD, Weatherall P, Thickman D, Hylton N, Warner E, Pisano E, Schnitt SJ, Gatsonis C, Schnall M, DeAngelis GA, Stomper P, Rosen EL, O'Loughlin M, Harms S, Bluemke DA, International … -
Magnetic resonance imaging of the breast: opportunities to improve breast cancer management.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005 Hylton N -
Four-phase single-capillary stepwise model for kinetics in arterial spin labeling MRI.
Magnetic resonance in medicine 2005 Li KL, Zhu X, Hylton N, Jahng GH, Weiner MW, Schuff N -
Magnetic resonance imaging of the breast prior to biopsy.
JAMA 2004 Bluemke DA, Gatsonis CA, Chen MH, DeAngelis GA, DeBruhl N, Harms S, Heywang-Köbrunner SH, Hylton N, Kuhl CK, Lehman C, Pisano ED, Causer P, Schnitt SJ, Smazal SF, Stelling CB, Weatherall PT, Schnall … -
Quantification of breast tissue index from MR data using fuzzy clustering.
Conference proceedings : ... Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual Conference 2004 Klifa C, Carballido-Gamio J, Wilmes L, Laprie A, Lobo C, Demicco E, Watkins M, Shepherd J, Gibbs J, Hylton N -
Evaluation of gadobenate dimeglumine for contrast-enhanced MRI of the breast.
AJR. American journal of roentgenology 2003 Hylton NM -
Magnetic resonance imaging in patients diagnosed with ductal carcinoma-in-situ: value in the diagnosis of residual disease, occult invasion, and multicentricity.
Annals of surgical oncology 2003 Hwang ES, Kinkel K, Esserman LJ, Lu Y, Weidner N, Hylton NM -
Magnetic resonance imaging for primary breast cancer management: current role and new applications.
Endocrine-related cancer 2002 Esserman L, Wolverton D, Hylton N -
Menstrual cycle variation of apparent diffusion coefficients measured in the normal breast using MRI.
Journal of magnetic resonance imaging : JMRI 2001 Partridge SC, McKinnon GC, Henry RG, Hylton NM -
MRI phenotype is associated with response to doxorubicin and cyclophosphamide neoadjuvant chemotherapy in stage III breast cancer.
Annals of surgical oncology 2001 Esserman L, Kaplan E, Partridge S, Tripathy D, Rugo H, Park J, Hwang S, Kuerer H, Sudilovsky D, Lu Y, Hylton N -
MR imaging of the breast in patients with positive margins after lumpectomy: influence of the time interval between lumpectomy and MR imaging.
AJR. American journal of roentgenology 2000 Frei KA, Kinkel K, Bonel HM, Lu Y, Esserman LJ, Hylton NM -
Integration of breast imaging into cancer management.
Current oncology reports 2000 Esserman LJ, Wolverton D, Hylton N -
Suspension of breast-feeding following gadopentetate dimeglumine administration.
Radiology 2000 Hylton NM -
Dynamic high-spatial-resolution MR imaging of suspicious breast lesions: diagnostic criteria and interobserver variability.
AJR. American journal of roentgenology 2000 Kinkel K, Helbich TH, Esserman LJ, Barclay J, Schwerin EH, Sickles EA, Hylton NM -
Dedicated Breast MRI Systems Working Group report.
Journal of magnetic resonance imaging : JMRI 1999 Hylton N -
Vascularity assessment of breast lesions with gadolinium-enhanced MR imaging.
Magnetic resonance imaging clinics of North America 1999 Hylton NM -
Contrast-Enhanced Magnetic Resonance Imaging to Assess Tumor Histopathology and Angiogenesis in Breast Carcinoma.
The breast journal 1999 Esserman L, Hylton N, George T, Weidner N -
Semi-automated analysis for MRI of breast tumors.
Studies in health technology and informatics 1999 Partridge SC, Heumann EJ, Hylton NM -
Utility of magnetic resonance imaging in the management of breast cancer: evidence for improved preoperative staging.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1999 Esserman L, Hylton N, Yassa L, Barclay J, Frankel S, Sickles E -
Technical aspects of breast magnetic resonance imaging.
Topics in magnetic resonance imaging : TMRI 1998 Hylton NM, Kinkel K -
Evaluation of the effects of intravascular MR contrast media (gadolinium dendrimer) on 3D time of flight magnetic resonance angiography of the body.
Journal of magnetic resonance imaging : JMRI 1996 Bourne MW, Margerun L, Hylton N, Campion B, Lai JJ, Derugin N, Higgins CB -
Imaging techniques for breast MR imaging.
Magnetic resonance imaging clinics of North America 1994 Hylton NM, Frankel SD -
Impact of section doubling on MR angiography.
Radiology 1992 Hylton NM, Simovsky I, Li AJ, Hale JD -
MRA: how it's done and what it shows.
Diagnostic imaging 1990 Hylton NM, Du LN, Winkler M -
Oblique reformatting of multislice magnetic resonance images for improved visualization of coronary arteries.
Journal of digital imaging 1990 Hylton NM, Chung WS, Botvinick EH, Schiller NB, Sheldon P, Kaufman L -
Characterization of arterial blood flow using magnetic resonance imaging techniques.
Monographs on atherosclerosis 1990 Hylton NM -
Echo-planar pediatric imager.
Radiology 1988 Crooks LE, Arakawa M, Hylton NM, Avram H, Hoenninger JC, Watts JC, Hale JD, Kaufman L -
Partial flip angle MR imaging.
Radiology 1987 Mills TC, Ortendahl DA, Hylton NM, Crooks LE, Carlson JW, Kaufman L -
The value of relaxation times and density measurements in clinical MRI.
Investigative radiology 1987 Crooks LE, Hylton NM, Ortendahl DA, Posin JP, Kaufman L -
Optimal visualization of the cerebrospinal fluid on MRI.
AJNR. American journal of neuroradiology 1986 Ortendahl DA, Posin JP, Hylton NM, Mills CM -
Information processing in magnetic resonance imaging.
Critical reviews in diagnostic imaging 1986 Hylton NM, Ortendahl DA -
Variable magnetic resonance imaging parameters: effect on detection and characterization of lesions.
Radiology 1985 Posin JP, Ortendahl DA, Hylton NM, Kaufman L, Watts JC, Crooks LE, Mills CM -
Multiple spin-echo magnetic resonance imaging.
Radiology 1985 Feinberg DA, Mills CM, Posin JP, Ortendahl DA, Hylton NM, Crooks LE, Watts JC, Kaufman L, Arakawa M, Hoenninger JC, Brant-Zawadzski M -
Analytical tools for magnetic resonance imaging.
Radiology 1984 Ortendahl DA, Hylton N, Kaufman L, Watts JC, Crooks LE, Mills CM, Stark DD -
Signal to noise in derived NMR images.
Magnetic resonance in medicine 1984 Ortendahl DA, Hylton NM, Kaufman L, Crooks LE -
NMR in experimental cerebral edema: value of T1 and T2 calculations.
AJNR. American journal of neuroradiology 1984 Brant-Zawadzki M, Bartkowski HM, Ortendahl DA, Pitts LH, Hylton NM, Nishimura MC, Crooks LE